First|in|Human Phase I Study of ABBV|085

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug ...

ABBV-085 appeared safe and tolerable at a dose of 3.6 mg/kg every 14 days, with preliminary antitumor activity noted in patients with ...

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments.

First-in-human phase 1 study of ABBV-085, an antibody-drug ...

This phase 1, first-in-human, 2-part study assessed the safety/tolerability of ABBV-085 in patients (pts) with advanced solid tumors.

First-in-Human Phase I Study of ABBV-085, an Antibody

First-in-Human Phase I Study of ABBV-085, an Antibody–. Drug Conjugate Targeting LRRC15, in Sarcomas and. Other Advanced Solid Tumors A C.

First-in-human phase I study of ABBV-085, an antibody–drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments.

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug ...

ABBV-085 is a monomethyl auristatin-E antibody-drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments. Herein, we ...

First-in-human phase I study of ABBV-085, an antibody–drug ...

First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors · Investigational Cancer ...

First-in-Human Phase I Study of ABBV-838, an Antibody ... - PubMed

ABBV-838 is an antibody-drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.

First-in-human study of ABBV-400, a novel c-Met–targeting antibody ...

A phase 1 study of ABBV-400 was initiated for adults with advanced solid tumors and progression on standard therapies (NCT05029882); results ...

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

This phase 1 study evaluates safety and clinical activity of ABBV-319 monotherapy in patients with relapsed or refractory (R/R) B-cell malignancies.

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug ...

... ID: 233035688. First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. @article ...

A Multicenter, Phase I, Open-Label, Dose-Escalation Study of ABBV ...

at least 4 weeks prior to first dose of ABBV-085. 3. Unresolved adverse events >= Grade 2 from prior anticancer therapy, except for alopecia. 4. Participant has ...

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug ...

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

Exploratory patient reported outcomes (PROs) from the Phase 2 LUMINOSITY trial, evaluating telisotuzumab vedotin (Teliso-V), a potential first ...

1185TiP First-in-human phase I study of ABBV-637 as monotherapy ...

ABBV-637 is an investigational agent that targets EGFR on tumor cells and delivers a targeted payload that specifically inhibits the pro-survival factor Bcl-xL.

First-in-human phase 1 study of ABBV-085, an antibody-drug ...

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. G ...

First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug ...

Conclusions: ABBV-085 appeared safe and tolerable at a dose of 3.6 mg/kg every 14 days, with preliminary antitumor activity noted in patients with osteosarcoma ...

770 Safety, efficacy, and pharmacokinetic results from a phase I first ...

Acknowledgements AbbVie and the authors thank all the trial investigators and the patients who participated in this clinical trial. Medical writing support ...

First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug ...

Figures for First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

First-in-human phase 1 study of ABBV-085, an antibody-drug ...

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. @article ...